Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323098 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
A Phase 3 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT04323098 is a Phase 3 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 22 participants.
The verdict
NCT04323098, a Phase 3 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
Interventions
- BIOLOGICAL valoctocogene roxaparvovec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04323098
The ClinicalTrials.gov registry entry for NCT04323098 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valoctocogene roxaparvovec is the first listed.
NCT04323098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04323098 about?
NCT04323098 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A". This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
What is the current status of trial NCT04323098?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2020-12-08. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT04323098?
The interventions under investigation include: valoctocogene roxaparvovec (BIOLOGICAL).
Who is sponsoring clinical trial NCT04323098?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.